PRADO: Phase II Trial of Response-Directed Surgery and Adjuvant Therapy Following Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma

June 3-7, 2022; Chicago, Illinois
PRADO confirmed high pathologic response rates with neoadjuvant ipilimumab + nivolumab in stage III melanoma and demonstrated good outcomes in patients with major pathologic responses not receiving therapeutic lymph node dissection and adjuvant therapy
Format: Microsoft PowerPoint (.ppt)
File Size: 281 KB
Released: June 13, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.

Related Content

Experts Michael A. Davies, MD, PhD, and Jeffrey S. Weber, MD, PhD, review key data in melanoma presented at the 2022 Society for Melanoma Research Annual Congress, from Clinical Care Options (CCO)

Michael A. Davies, MD, PhD Jeffrey S. Weber, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 19, 2022 Expired: December 18, 2023

Dr Michael Davies highlights key studies presented at the 2022 Society for Melanoma Research Annual Congress in this commentary from Clinical Care Options (CCO)

Michael A. Davies, MD, PhD Released: November 17, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Download slides on selected studies from the 2022 Society for Melanoma Research Annual Congress, as reported by Clinical Care Options (CCO)

Released: October 31, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings